Pathophysiology of β2-glycoprotein i in antiphospholipid syndrome

Lupus

Volumn 19, Issue 4, 2010, Pages 379-384

  Matsuura, E ^a   Shen, L ^a   Matsunami, Y ^a   Quan, N ^a   Makarova, M ^a   Geske, F J ^b   Boisen, M ^b   Yasuda, S ^b   Kobayashi, K ^a   Lopez, L R ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b Division of Medicine   (United States)

Author keywords

2 glycoprotein I fibrinolysis; Angiogenesis; Atherosclerosis; Pro coagulation

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; EPITOPE; FIBROBLAST GROWTH FACTOR; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY;

ANGIOGENESIS; ANTIBODY AFFINITY; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNITY; BLOOD CLOTTING; DISEASE ASSOCIATION; DISEASE COURSE; FIBRINOLYSIS; HUMAN; LIPID PEROXIDATION; METABOLITE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; THROMBOSIS; VASCULAR DISEASE; ANIMAL; IMMUNOLOGY; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION; EPITOPES; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSIS;

EID: 77951246557     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310361352     Document Type: Review

References (50)

1. Bouma B., de Groot PG, van den Elsen JM, et al. Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. Embo J 1999 ; 18: 5166-5174. (Pubitemid 29465567)
2. Schwarzenbacher R., Zeth K., Diederichs K., et al. Crystal structure of human β2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. Embo J 1999 ; 18: 6228-6239. (Pubitemid 29533227)
3. Hasunuma Y., Matsuura E., Makita Z., et al. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997 ; 107: 569-573. (Pubitemid 27102148)
4. Kobayashi K., Kishi M., Atsumi T., et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003 ; 44: 716-726. (Pubitemid 37279673)
5. Pittoni V., Ravirajan CT, Donohoe S., et al. Human monoclonal anti-phospholipid antibodies selectively bind to membrane phospholipid and β2-glycoprotein I (β2-GPI) on apoptotic cells. Clin Exp Immunol 2000 ; 119: 533-543. (Pubitemid 30146352)
6. Nimpf J., Bevers EM, Bomans PH, et al. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein-I. Biochim Biophys Acta 1986 ; 884: 142-149. (Pubitemid 16007960)
7. Schousboe I., Rasmussen MS Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by β2-glycoprotein I and anti- β2-glycoprotein I. Thromb Haemost 1995 ; 73: 798-804.
8. Nimpf J., Wurm H., Kostner GM Interaction of β2-glycoprotein-I with human blood platelets: influence upon the ADP-induced aggregation. Thromb Haemost 1985 ; 54: 397-401. (Pubitemid 16252457)
9. Ieko M., Tarumi T., Takeda M., et al. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. J Thromb Haemost 2004 ; 2: 612-618. (Pubitemid 40185685)
10. Mori T., Takeya H., Nishioka J., et al. β2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost 1996 ; 75: 49-55. (Pubitemid 26051194)
11. Sheng Y., Reddel SW, Herzog H., et al. Impaired thrombin generation in β2-glycoprotein I null mice. J Biol Chem 2001 ; 276: 13817-13821. (Pubitemid 37391759)
12. Hoeg JM, Segal P., Gregg RE, et al. Characterization of plasma lipids and lipoproteins in patients with β2-glycoprotein I (apolipoprotein H) deficiency. Atherosclerosis 1985 ; 55: 25-34. (Pubitemid 15064936)
13. Bancsi LF, van der Linden IK, Bertina RM β2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992 ; 67: 649-653.
14. Matsuura E., Kobayashi K., Tabuchi M., et al. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 2006 ; 45: 466-486. (Pubitemid 44331411)
15. Shi W., Chong BH, Hogg PJ, et al. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993 ; 70: 342-345. (Pubitemid 23222496)
16. Takeya H., Mori T., Gabazza EC, et al. Anti-β2-glycoprotein I (β2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β2GPI binding to phospholipids. J Clin Invest 1997 ; 99: 2260-2268. (Pubitemid 27203784)
17. Marciniak E., Romond EH Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989 ; 74: 2426-2432. (Pubitemid 19286462)
18. Ieko M., Ichikawa K., Triplett DA, et al. β2-Glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999 ; 42: 167-174. (Pubitemid 29042583)
19. Amengual O., Atsumi T., Khamashta MA, et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998 ; 79: 276-281. (Pubitemid 28065869)
20. Branch DW, Rodgers GM Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993 ; 168: 206-210.
21. Kornberg A., Blank M., Kaufman S., et al. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994 ; 153: 1328-1332. (Pubitemid 24228525)
22. Conti F., Sorice M., Circella A., et al. β2-glycoprotein I expression on monocytes is increased in anti-phospholipid antibody syndrome and correlates with tissue factor expression. Clin Exp Immunol 2003 ; 132: 509-516. (Pubitemid 36713959)
23. Lutters BC, Derksen RH, Tekelenburg WL, et al. Dimers of β2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem 2003 ; 278: 33831-33838.
24. Raschi E., Testoni C., Bosisio D., et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003 ; 101: 3495-3500. (Pubitemid 36857933)
25. Hunt JE, Simpson RJ, Krilis SA Identification of a region of β2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993 ; 90: 2141-2145.
26. Ohkura N., Hagihara Y., Yoshimura T., et al. Plasmin can reduce the function of human β2 glycoprotein I by cleaving domain V into a nicked form. Blood 1998 ; 91: 4173-4179. (Pubitemid 28261980)
27. Matsuura E., Igarashi J., Kasahara H., et al. Proteolytic cleavage of β2-glycoprotein I: reduction of antigenicity and the structural relationship. Intern Immunol 2000 ; 12: 1183-1192. (Pubitemid 30616223)
28. Horbach DA, van Oort E., Lisman T., et al. β2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999 ; 81: 87-95. (Pubitemid 29041656)
29. Yasuda S., Atsumi T., Ieko M., et al. Nicked β2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004 ; 103: 3766-3772. (Pubitemid 38596293)
30. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992 ; 267: 10931-10934.
31. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995 ; 1: 27-31.
32. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996 ; 86: 353-364. (Pubitemid 26272076)
33. Cao Y., Ji RW, Davidson D., et al. Kringle domains of human angiostatin: characterization of the antiproliferative activity on endothelial cells. J Biol Chem 1996 ; 271: 29461-29467. (Pubitemid 26382666)
34. Gately S., Twardowski P., Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997 ; 94: 10868-10872. (Pubitemid 27430827)
35. Hunt JE, Simpson RJ, Krilis SA Identification of a region of β2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993 ; 90: 2141-2145.
36. Yasuda S., Atsumi T., Ieko M., et al. Nicked β2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004 ; 103: 3766-3772. (Pubitemid 38596293)
37. Hughes GR, Harris EN, Gharavi AE The anticardiolipin syndrome. J Rheumatol 1986 ; 13: 486-489.
38. Matsuura E., Igarashi Y., Yasuda T., et al. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid surface. J Exp Med 1994 ; 179: 457-462. (Pubitemid 24058733)
39. Inanc M., Radway-Bright EL, Isenberg DA β2-glycoprotein I and anti-β2-glycoprotein I antibodies Where are we now?. Br J Rheumatol 1997 ; 36: 1247-1257.
40. Brey RL, Abbott RD, Curb JD, et al. β2-glycoprotein I dependent anticardiolipin antibodies and the risk of ischemic stroke and myocardial infarction. Stroke 2001 ; 32: 1701-1706.
41. Frostegard J., Svenungsson E., Wu R., et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005 ; 52: 192-200. (Pubitemid 40129248)
42. Cervera R., Piette JC, Font J., et al. Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002 ; 46: 1019-10127. (Pubitemid 34303815)
43. Nicolo D., Monestier M. Antiphospholipid antibodies and atherosclerosis. Clin Immunol 2004 ; 112: 183-189. (Pubitemid 38881484)
44. George J., Harats D., Gilburd B., et al. Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999 ; 99: 2227-2230. (Pubitemid 29201126)
45. Kobayashi K., Kishi M., Atsumi T., et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implications as an atherogenic autoantigen. J Lipid Res 2003 ; 44: 716-726. (Pubitemid 37279673)
46. Lopez LR, Simpson DF, Hurley BL, et al. OxLDL/β2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis and antiphospholipid syndrome. Pathogenic implications for vascular involvement. Ann NY Acad Sci 2005 ; 1051: 313-322.
47. Greco TP, Conti-Kelly AM, Greco T. Jr, et al. Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Am J Clin Pathol 2009 ; 132: 613-620.
48. Yamaguchi Y., Seta N., Kaburaki J., et al. Excessive exposure to anionic surfaces maintains autoantibody response to β2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007 ; 110: 4312-4318. (Pubitemid 351377796)
49. Kajiwara T., Yasuda T., Matsuura E. Intracellular trafficking of β2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome. J Autoimmun 2007 ; 29: 164-173. (Pubitemid 47385117)
50. Kobayashi K., Tada K., Itabe H., et al. Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 2007 ; 16: 929-938.